OBJECTIVE: To undertake a systematic review and network meta-analysis (NMA) to compare the effectiveness among the different regimens of Salvia miltiorrhiza injection classes (SMICs) for unstable angina pectoris (UAP) treatment.
INTRODUCTION
Unstable angina pectoris (UAP) is a common coronary syndrome which has the characteristic of progressive deterioration. UAP can worsen readily and lead to myocardial infarction or sudden death. 1 Research has shown that ≈30% of patients with UAP develop myocardial infarction within 3 months. 2 Physicians trained in Traditional Chinese Medicine (TCM) consider UAP to belong to "thoracic obstruction" or "cardiodynia", the key pathogenesis of which is Qi-deficiency and blood stasis. 3 Danshen (Radix Salviae Miltiorrhizae) is the dried root and rhizome of Salvia miltiorrhiza. Danshen (Radix Salviae Miltiorrhizae) is a common TCM and used widely to treat coronary heart disease and cerebrovascu-lar disease. Danshen (Radix Salviae Miltiorrhizae) contains the lipid-soluble components tanshinone I, tanshinone Ⅱ A, cryptotanshinone and dihydrotanshinone as well as the water-soluble components tanshinol and salvianolic acid B (SalB). 4 Danshen (Radix Salviae Miltiorrhizae) can: relax coronary artery muscle directly; improve the microcirculation by promoting blood circulation; remove blood stasis; inhibit blood clotting; reduce blood viscosity; significantly improve the hyper-viscosity of blood; inhibit thrombogenesis. 5 Danshen (Radix Salviae Miltiorrhizae) is bitter and gives a slightly cold sensation when it enters the heart and liver meridians. The major functions of this herb in TCM are activating blood circulation to disperse stasis, nourishing the heart to calm the mind, and tranquilizing the mind by nourishing the heart. 6 Several traditional Chinese injections contain Danshen (Radix Salviae Miltiorrhizae), and are termed "Salvia miltiorrhiza injection classes" (SMICs). These include Danshen injection (DS), Danhong injection (DH), Salvianolate injection (SI), and Guanxinning injection (GXN), and are used widely for UAP treatment. Several Meta-analyses [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] have demonstrated that SMICs such as DH, SI and GXN, as adjuvant treatment for conventional treatment of UAP, are beneficial compared with conventional treatment alone in terms of the total efficacy against UAP, reducing fibrinogen content, adjusting blood lipid levels, and correcting T-wave inversion. However, the comparative effectiveness of SMICs with each other is not known, mainly because of the restrictions of using different interventions together. "Network Meta-analysis" (NMA) is a method in which multiple treatments are compared using direct comparisons of interventions within randomized controlled trials (RCTs) and indirect comparisons across RCTs based on a common comparator. [18] [19] [20] To establish the optimal treatment for UAP, we did a comprehensive NMA to integrate all available information from RCTs to compare the effectiveness of SMICs.
METHODS

Inclusion criteria
Studies had to meet three main criteria. The first criterion was the type of study, which had to be a RCT reporting on the efficacy of SMICs as adjuvant treatment for UAP, regardless of blinding. The second criterion was the patient. The diagnosis of UAP was according to the 2014 American Heart Association/American College of Cardiology Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes 21 or the diagnosis of UAP released by the cardiovascular-disease branch of the Chinese Medical Association in 2000. 22 No limit was placed on age, sex, ethnicity or disease severity. The final criterion was interventions. These were classified according to recommendation from international guidelines for UAP treatment. 23 The main drugs used in Western Medicine (WM) were antiplatelet agents, nitroglycerine, beta-blockers, long-acting calcium-channel blockers, and angiotensin-converting-enzyme inhibitors. We called these drugs, used alone or in combination, "chemotherapy" (CT). Eligible comparisons for our study were: SMICs plus CT versus CT; SMICs plus CT versus SMICs plus CT. None of participants received any other Chinese medicine, surgical procedure or acupuncture.
Exclusion criteria
The studies were excluded if they met the following criteria: (a) data were incorrect or incomplete; (b) participants had other serious diseases, such as acute myocardial infarction, severe heart failure, disturbance of blood coagulation, or disease of the liver or kidneys; (c) patients were undergoing surgery, acupuncture or other physical therapy; (d) treatment was combined with another herbal medicine in experimental or control groups; (e) studies do not meet the standard for evaluation of the curative effect.
Outcome measurements
Outcome measurements were: (a) total efficacy against UAP (significantly effective + effective); (b) total effectiveness of electrocardiography (ECG); (c) cardiovascular events. According to guidelines for the criteria of the curative effect of UAP and ECG set by the Chinese Medicine Society 24 , the efficacy criterion was classified as "significantly effective", "effective", and "invalid". "Significantly effective" was documented if symptoms disappeared or improved significantly, the frequency of chest pain decreased to 80% , and ECG returned to normal. "Effective" was documented if symptoms were relieved, the frequency of chest pain decreased to 50%-80% , the ST-segment recovered ≥ 0.05 mV (but not to normal), the main lead T-wave changed from flat to vertical, or T-wave inversion was > 50%. "Invalid" was documented if symptoms did not change or worsened, the frequency of chest pain did not decrease (or even increased), and ST-T waves did not change or worsened. 
Data sources and search strategies
Data extraction
The data of interest from each included RCT were collected using a standard data-abstraction form created in Excel 2013™ (Microsoft, Redmond, WA, USA). The main components of the extracted data were: (a) general information (authors' names and publication data); (b) patient information (median age, number of patients, sex); (c) intervention (names, doses, and treatment); (d) outcomes (total efficacy against UAP, total effectiveness of ECG, cardiovascular events).
Risk of bias in individual studies
Assessment of the risk of bias was evaluated according to the Cochrane Risk of Bias tool. This tool comprises: random-sequence generation (selection bias); allocation concealment (selection bias); blinding of participants and personnel (performance bias); blinding of outcome assessment (detection bias); incomplete outcome data (attrition bias); selective reporting (reporting bias); others bias. Each parameter was divided into three grades, "high", "unclear", and "low". "High" refers to incorrect random methods, no allocation concealment, or no blinding. "Unclear" denotes no description in the text and thus it is unknown. "Low" refers to correct randomization methods, appropriate blinding without violation through implementation, and detailed description in the article. 25 Disagreements were resolved by a third researcher (Zhang Dan) .
Statistical analyses
We undertook pairwise Meta-analyses using RevMan 5.3 (Cochrane Collaboration, Copenhagen, The Nordic Cochrane Centre). Data were summarized using odds ratios (ORs) with 95% confidence intervals (95% CIs). The chi-squared test and I 2 statistic were used to assess the heterogeneity between included studies. 26 P ≥ 0.1, and I 2 ≤ 50% suggested no statistical heterogeneity and a fixed-effects model was used for meta-analysis. If P < 0.1 and I 2 > 50% , then a random-effects model was used. Subsequently we conducted a random-effect NMA if sufficient data on the same outcome were available. 27 STATA 13.0 (MRC Biostatistics Unit, Cambridge, UK) with network command 28 was applied for NMA. NMA synthesized information from a network of related studies comparing more than two treatments in UAP patients. The treatment effects of all treatment regimens were estimated by applying a two-stage NMA. Using the "expand" command, we expanded summary data into individual patient data in STATA.
Poisson regression was applied to estimate the log (OR) and variance-covariance of each treatment pairwise using the "Meta command". Pooled ORs and their 95% CIs were then estimated using a multivariate random-effect meta-analysis. To evaluate the inconsistency between estimates of direct and indirect effects for the same comparison, we evaluated each closed loop in the network. In one closed loop, we used the inconsistency factor to evaluate the heterogeneity among studies. If 95% CIs of ratios of odds ratios (ROR) values are truncated at 1, then good consistency is suggested. 29 To create a rank of treatments, we used the surface under the cumulative ranking probabilities (SUCRA). 30 To account for both outcomes, we used multivariate methods to determine the dependency between outcomes. Clustering methods and two-dimensional plots were used to produce clusters of treatments. 28 Using the "clustering" command, clustered ranking plots can be obtained using the STATA program. The different colors correspond to the estimated clusters, and were used for grouping the treatments according to their similarity for both outcomes. Figure 1 shows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram. The literature search yielded 3012 articles in total that met the search criteria. After excluding duplications, reviews, and obviously irrelevant articles by reading titles and abstracts, 610 articles were downloaded for further analyses. Through reading the full text, 111 studies were included in the NMA. All studies were published in Chinese from 2003 to 2016. Table 1 provides a summary of the included studies. The 111 RCTs involved 10 500 participants, with sample sizes varying from 26 to 300. All RCTs were conducted among Chinese populations in China. There were more male patients (58.6% ) than female cases. Figure 2 shows a network graph comparing injections of DS, DH, SI, and GXN. There were 10 pairwise comparisons, including seven direct comparisons. Each node represents an intervention, whereas the node size represents the sample size and the width of the connecting line between each node represents the number of studies reporting the comparison. The duration of treatment for experimental and control groups was ≤ 15 d (most were 14 d).
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RESULTS
Study selection
Characteristics of included studies
Quality of the included studies
We used the Cochrane Risk of Bias Assessment tool 25 to conduct a quality evaluation on the included studies. We found that 10 articles used a random number table, four articles mentioned blinding, and the remaining studies did not provide information on randomization or blinding. All studies had an unclear risk of bias with regard to allocation concealment. All included trials did not have incomplete outcome data. Therefore, the methodological quality of included studies was "poor". Details on the risk of bias are shown in Figure 3 .
Pairwise meta-analysis One-hundred and eleven studies reported the total efficacy against UAP. In these RCTs, 10 500 patients were involved, and five regimens were included. Table 2 summarizes the results of pairwise meta-analysis regarding the total efficacy against UAP. There was no significant heterogeneity in the pairwise meta-analyses (I 2 < 50%, P > 0.1). There were seven direct comparisons, four of which were SMICs plus CT versus CT. Compared with CT alone, all agents were more beneficial in improving the total efficacy against UAP (DS plus CT versus CT: OR = 2.80, 95% CI: 1. 49 Nitrates, low-molecular-weight heparin, etc.
Aspirin, nitrates, beta-blockers, calcium antagonist, angiotensin converting enzyme inhibitors, statins, etc.
Treatment (d)  10  14  10  14  15  14  14  14  10  14  14  14  14  14  14  14  15  14  14  14  15  7  14  14 Outcome Yang LG 2014 96 Ou JH 2014 97 Wang ZP et al 2014 98 Wang HX 2014 99 Pu DY 2014 100 Zheng MR 2014 101 Huang MH 2014 102 Liu HX et al 2015 103 Kang HP 2015 104 Zhao B et al 2015 105 Hao HB 2015 106 Chen JH et al 2015 107 Yang Nitrates, aspirin, beta-blockers, calcium antagonists, etc.
Seventy-seven RCTs involving 7830 patients reported on the total effectiveness of ECG. Table 3 summarizes the results of pairwise meta-analysis. There was no significant heterogeneity in the pairwise meta-analyses (I 2 < 50%, P > 0.1) except for DH plus CT versus DS plus CT. There were seven direct comparisons, four of which were SMICs plus WM versus WM, and three of them compared different SMICs. The following treatment comparisons were significant for improving the total effectiveness of ECG: DH plus WM versus WM (OR = 2.65, 95% CI: 2.31-3.03); SI plus WM versus WM (2.69, 2.02-3.57); GXN plus WM versus WM (4.04, 2.24-7.29). Other treatment comparisons failed to reach significance (the 95% CI included 0).
NMA
Next, all available within-study comparisons were synthesized by NMA. Table 3 Then, all available within-study comparisons were synthesized by NMA and are shown in Table 4 . The following treatment comparisons were significant for improving the total effectiveness of ECG: DH plus CT versus CT (OR = 2.65, 95% CI: 2.32-3.03); SI plus CT versus CT (2.79, 2.14-3.64); GXN plus CT versus CT (3.56, 2.40-5.28); DH plus CT versus DS plus CT (2.03, 1.31, 3.14); SI plus CT versus DS plus CT (2.13, 1.29-3.53); GXN plus CT versus DS plus CT (2.72, 1.51-4.89). Other treatment comparisons failed to reach significance (the 95% CI included 0).
Inconsistency test
In Figure 4A and B, four triangular loops are present in the NMA: CT-DS-SI, CT-DS-DH, CT-DH-SI, and Notes: M: male; F: female; AVG: average; E: experimental group; C: control group; DS: Danshen injection; DH: Danhong injection; SI: salvianolate injection; GXN: Guanxinning injection; CT: chemotherapy; (1): total efficacy against unstable angina pectoris; (2) DS-DH-SI. The 95% CI of ROR values was truncated at 1, suggesting no significant inconsistency in the study.
Ranking probability
Ranking probability analysis ( Figure 5) showed that SI plus CT had the highest probability of being the best treatment for the total efficacy against UAP (SUCRA = 82.8%), followed by GXN plus CT (76.4%), DH plus CT (65.6% ), DS plus CT (24.8% ) and CT (0.4% ). For the total effectiveness of ECG (Figure 6 ), GXN plus CT had the highest probability of being the best treatment (SUCRA = 93.7%), followed by SI plus CT (69.4%), DH plus CT (61.8%), DS plus CT (22.3%) and CT (2.7%).
Cardiovascular events
For UAP, the prevention of cardiovascular events should be the most important benefit. However, only five studies referred to cardiovascular events, and all were qualitative descriptions (Table 5) . Simultaneous ranking of the interventions for two outcomes Clustered ranking plots of the network for the total effectiveness of UAP and ECG are shown in Figure 7 .
The upper-right corner shows that GXN plus CT, SI plus CT, and DH plus CT were significantly better outcomes in UAP patients. 
DISCUSSION
We wished to evaluate the effectiveness of SMICs with conventional therapy for UAP. NMA methodology was used to derive relative estimates by combining direct and indirect evidence in the absence of robust evidence from head-to-head comparisons in clinical trials. Studies on SMIC therapy have used Meta-analyses to evaluate the efficacy of DH, [7] [8] [9] [10] [11] [12] SI, [13] [14] [15] [16] and GXN 17 plus CT versus CT for UAP. Our Meta-analysis suggested that SMICs as an adjuvant treatment of CT for UAP was beneficial compared with CT alone in direct comparisons. However, comparison of the effectiveness of SMICs with each other for UAP based on the results of direct Meta-analysis was difficult because there are many treatment regimens, and too few studies undertaking the same treatment comparisons for pooling. This is the first indirect comparison using a network approach to compare each treatment. After synthesizing 111 RCTs, we found evidence that most of SMICs had comparable effects on UAP. With regard to the total efficacy against UAP and effectiveness of ECG, NMA indicated that treatment with SMICs plus CT was significantly inferior to CT alone. SMICs have the advantages of preventing cardiovascular events. Our results are consistent with published Meta-analyses. By comprehensive direct and indirect comparisons, this NMA provided clear ranking and optimal options by comparing the clinical efficacy of SMICs plus CT for UAP treatment. Clinical trials directly comparing SMICs with each other are lacking. Our review is the first to assess: DH plus CT versus DS plus CT; SI plus CT versus DS plus CT; SI plus CT versus DH plus CT. Meanwhile, we applied NMA to assess: GXN plus CT versus DS plus CT; GXN plus CT versus SI plus CT; GXN plus CT versus DH plus CT. The present study demonstrated that treatment with DH plus CT was significantly inferior to DS plus CT against UAP (OR = 2.24, 95% CI: 1.38-3.65) and for the total effectiveness of ECG (2.03, 1.31-3.14). SI plus CT was more beneficial than DS plus CT against UAP (OR = 2.49, 95% CI: NMA suggested that SI had the highest SUCRA values, implying that SI was the optimal treatment regimen to increase the total efficacy against UAP. SI extracted from Salvia miltiorrhiza clearly had efficacious components that were pharmacologically active upon multiple targets. These components may enhance the activities of endogenous anti-oxidative enzymes, antiplatelet aggregation, and antithrombotic effects. 141 GXN had the highest SUCRA values, implying that GXN was the optimal treatment regimen to increase the total effectiveness of ECG. GXN is composed of Danshen (Radix Salviae Miltiorrhizae) and Chuanxiong (Rhizoma Chuanxiong). Combination treatment can inhibit platelet aggregation, and prompt the stability of atherosclerotic plaques. The clustered ranking according to two outcomes revealed that GXN plus CT, SI plus CT, and DH plus CT had the highest probability of being the best treatment. Atherothrombosis is the major cause of acute coronary syndromes. 144 Several studies have demonstrated that the adhesion, activation and aggregation of platelets have important roles in atherothrombosis. 145 SMICs are of great importance in UAP treatment because they contain the water-soluble components tanshinol and SalB, 4 which have antiplatelet aggregation, antithrombotic 144 and anti-arrhythmic protective effects and improve hemorheology. 145 From the perspective of pharmacologic research, SalB (the most abundant member of salvianolic acids) plays an important part in inhibiting myocardial injury, promoting cardiac angiogenesis, protecting myocardial cells, and stimulating the production of nitric oxide in endothelial cells. 146 Our results had certain shortcomings that might have undermined the validity of the overall findings. First, all the included trials claimed randomization but the details of random-sequence generation were not described in most of them, and allocation concealment was not reported in any of them. These gaps may have resulted in bias for patient selection. Four studies mentioned blinding, and the remaining studies did not provide information on blinding, leading to a potential risk of overestimation of SMIC effectiveness. These defects might have reduced the validity and value of the evidence examined in our NMA. Some scholars have claimed that the poor quality of these reports is most likely caused by irregular reporting as opposed to flaws in their design and execution. Also, the results are usually more important than the methodology in China, which can lead to vague methodology. Hence, we appeal for future SMIC studies to have more rigorous designs and reporting criteria.
Second, for UAP patients, myocardial infarction or sudden death may occur after leaving hospital. The prevention of cardiovascular events should be the most important benefit. However, only five studies referred to cardiovascular events. Data from cardiac angiography is important for UAP treatment, but only six of the included RCTs provided relevant information. The dose/ frequency of use of nitroglycerine and the prevalence of acute attacks of angina are the important indices to measure the quality of life of UAP patients. However, few RCTs provided relevant information, and the units employed were different. Future clinical trials should pay more attention to this information. Third, head-to-head clinical trials provide the highest level of evidence when comparing interventions. However, only 7 of 111 included studies were SMICs compared with each other. As such, an indirect treatment comparison provides the next-best evidence for the relative differences between treatments in the absence of direct comparisons. Large RCTs are needed to compare SMICs with each other directly. In summary, our study suggested that SI plus CT was the optimal treatment regimen for UAP in improving the total efficacy against UAP. GXN plus CT was the optimal treatment regimen for UAP with regard to improving the total effectiveness of ECG. With regard to these two parameters, SI, DH, and GXN were the optimal treatment regimens for UAP. However, our findings relied on original studies, with several methodological questions arose regarding the quality of the included studies. Therefore, large-scale and well-designed RCTs are required to confirm the efficacy of SMICs in patients with UAP.
